Celsion's Prospects For A Significant Upside Just Got A Lot Better
Clinically Sound Investor
Clinically Sound Investor
Tue, Apr. 19, 9:17 AM
Dec. 16, 2015, 9:14 AM
Oct. 12, 2015, 10:44 AM
- Thinly traded nano cap Celsion (CLSN +9.2%) moves up on a healthy 10x surge in volume in response to its announcement of positive preclinical results for its GEN-1 IL-12 immunotherapy. Specifically, the combination of GEN-1 IL-12 with Roche's (OTCQX:RHHBY +0.7%) Avastin (bevacizumab) and J&J's (JNJ +0.9%) Doxil (doxorubicin HCl liposome injection) showed a greater than 98% reduction in tumor burden compared to the combination of Avastin and Doxil alone in an ovarian cancer cell line called SKOV3 implanted into immunocompromised mice.
- GEN-1 is an immunotherapy consisting of an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system. It is administered via an intraperitoneal (body cavity) injection.
- The company is currently enrolling patients in a Phase 1b trial called OVATION. A Phase 1/2 combination study should commence in mid-2016.
Oct. 12, 2015, 9:13 AM
Aug. 6, 2015, 9:27 AM
- Thinly traded nano cap Celsion (NASDAQ:CLSN) is up 8% premarket on light volume in response to its announcement of the latest overall survival (OS) data from its Phase 3 study, called HEAT, evaluating ThermoDox in combination with radiofrequency ablation (RFA) in primary liver cancer.
- As of July 15, treatment with the combination showed a 58% improvement in overall survival in a subgroup of subjects (n=285/701) compared to RFA alone (p=0.0198). Median OS for the ThermoDox cohort was 79 months versus 53.6 months in the RFA-only cohort.
- A post-hoc slice-and-dice of the data showed a ThermoDox treatment effect in Chinese patients with single lesions but it was not statistically significant.
Aug. 6, 2015, 9:15 AM
Jul. 15, 2015, 10:36 AM
- Celgene's (CELG +9.5%) $7.2B deal for Receptos (RCPT +10.3%) is “a great acquisition at a great price," Nomura analysts say, as ozanimod could enable CELG's inflammation and immunology franchise to double peak sales to $10B and reduce reliance on Revlimid to drive future growth, and the acquisition price of less than 2x peak sales is a steep discount relative to recent comparisons.
- Wedbush analyst Liana Moussatos sees plenty of potential upside to justify a rival bidder stepping in for RCPT, noting that she had estimated the company could be valued at $348/share, or ~$10.9B, in a buyout, substantially more than CELG's $232 offer.
- The deal is boosting some biotech names (IBB +1.9%), including PTC Therapeutics (PTCT +11.7%), Celsion (CLSN +7.1%) and Arena Pharmaceuticals (ARNA +6.7%).
Jul. 15, 2015, 9:15 AM
Jul. 14, 2015, 9:19 AM
Jul. 6, 2015, 9:10 AM
Apr. 15, 2015, 12:45 PM
Apr. 15, 2015, 9:21 AM
- Thinly-traded nano cap Celsion (NASDAQ:CLSN) jumps 32% premarket on robust volume in response to its announcement of positive interim results from a Phase 2 study assessing ThermoDox in combination with mild hyperthermia in patients with recurrent chest wall breast cancer, a type of cancer highly resistant to treatment.
- Out of the 16 enrolled patients, 12 were eligible for evaluation for efficacy. Eight (67%) experienced a clinical benefit while seven (58%) showed a local response, including five complete responses, two partial responses and one with stable disease.
- Enrollment should be completed in Q3.
- ThermoDox is encapsulated doxorubicin. After infusion, it is heated to a specific temperature which releases the cancer drug directly into a tumor.
Apr. 15, 2015, 9:18 AM
Feb. 20, 2015, 9:29 AM
- Thinly-traded nano cap Celsion (NASDAQ:CLSN) is up 12% premarket on increased volume in response to its update on its advancement of GEN-1, its DNA-based immunotherapy, for the front-line treatment of advanced platinum-resistant and recurring ovarian cancer.
- The FDA has cleared the Phase 1 dose escalation trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer. The trial should commence at five to six U.S. medical centers by mid-year.
- The company presents clinical and preclinical data showing the safety, biological activity and clinical benefits of GEN-1 today at the Molecular Medicine TRI-Conference in San Francisco. In an earlier Phase 1 study, GEN-1 demonstrated a disease control rate (DCR) of 31% and median overall survival (OS) of 18 months. In a Phase 2 study, it demonstrated a DCR of 45% and median OS of 10 months. DCR is the proportion of patients who show a response to treatment.
Feb. 20, 2015, 9:16 AM
Jul. 28, 2014, 9:12 AM
Celsion Corp. engages in the provision of oncology drug development services. It operates through developing and commercializing chemotherapeutic oncology drugs based on proprietary heat-activated liposomal technology. Its products include ThermoDox, TheraPlas, and TheraSilence. The company was... More
Country: United States
Other News & PR